Refinement of the population pharmacokinetic model for the monoclonal antibody matuzumab: External model evaluation and simulations

Clinical Pharmacokinetics

Volumn 48, Issue 7, 2009, Pages 477-487

  Kuester, Katharina ^a,c   Kovar, Andreas ^b   Lüpfert, Christian ^b   Brockhaus, Brigitte ^b   Kloft, Charlotte ^a,c  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b MERCK KGAA   (Germany)

^c MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; GEMCITABINE; MATUZUMAB;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER THERAPY; CLINICAL TRIAL; COLON CARCINOMA; COMPUTER PROGRAM; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PANCREAS CARCINOMA; PRIORITY JOURNAL; RECTUM CARCINOMA; SIMULATION; STEADY STATE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMPUTER SIMULATION; DATA COLLECTION; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; MODELS, BIOLOGICAL; NEOPLASMS;

EID: 68949199572     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11313400-000000000-00000     Document Type: Article

References (48)

1. De Luca A, Carotenuto A, Rachiglio A, et al. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559-67
2. Cohen S, Carpenter G, King Jr L, et al. Epidermal growth factor-receptor-protein kinase interactions: co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980; 255: 4834-42
3. Oda K, Matsuoka Y, Funahashi A, et al. A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 2005; 1: 2005-10
4. Baselga J. The EGFR as a target for anticancer therapy: focus on cetuximab. Eur J Cancer 2001; 37 Suppl. 4: S16-22
5. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist 2002; 7 Suppl. 4: 2-8
6. Baselga J. New therapeutic agents targeting the epidermal growth factor receptor. J Clin Oncol 2000; 18: 54S-9S
7. Goel S, Mani S, Perez-Soler R. Tyrosine kinase inhibitors: a clinical perspective. Curr Oncol Rep 2002; 4: 9-19
8. Raymond E, Faivre S, Armand JP. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs 2000; 60 Suppl. 1: 15-23; discussion 41-2
9. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351: 337-45
10. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999; 53: 167-76
11. Brabender J, Danenberg KD, Metzger R, et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-5
12. Ohsaki Y, Tanno S, Fujita Y, et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 2000; 7: 603-7
13. Hemming AW, Davis NL, Kluftinger A, et al. Prognostic markers of colorectal cancer: an evaluation ofDNAcontent, epidermal growth factor receptor, and Ki-67. J Surg Oncol 1992; 51: 147-52
14. Bruno R, Washington CB, Lu JF, et al. Population pharmacokinetics of trastuzumab in patients with HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2005; 56: 361-9
15. Ritter CA, Arteaga CL. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30: 3-11
16. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31: 637-43
17. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002; 94: 1593-611
18. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody. Drugs Today (Barc) 2005; 41: 107-27
19. Office of Oncology Drug Products, US FDA Center for Drug Evaluation and Research. Erbitux (cetuximab) approved for use in combination with radiation therapy [media release]. 2006 Jul 20 [online]. Available from URL: http://www.fda.gov/cder/Offices/OODP/whatsnew/cetuximab.htm [Accessed 2008 May 18]
20. US FDA Center forDrug Evaluation and Research. FDA expands labeling for cetuximab (marketed as Erbitux) [media release]. 2007 Oct 12 [online]. Available from URL: http://www.fda.gov/cder/Offices/OODP/whatsnew/centuximab200710.htm [Accessed 2008 May 18]
21. Socinski MA. Antibodies to the epidermal growth factor receptor in non small cell lung cancer: current status ofmatuzumab and panitumumab. Clin Cancer Res 2007; 13: s4597-601
22. Vallbohmer D, Lenz HJ. Epidermal growth factor receptor as a target for chemotherapy. Clin Colorectal Cancer 2005; 5 Suppl. 1: S19-27
23. Graeven U, Kremer B, Sudhoff T, et al. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer 2006; 94: 1293-9
24. Rodeck U, Williams N, Murthy U, et al. Monoclonal antibody 425 inhibits growth stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J Cell Biochem 1990; 44: 69-79
25. Murthy U, Basu A, Rodeck U, et al. Binding of an antagonistic monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch Biochem Biophys 1987; 252: 549-60
26. Kettleborough CA, Saldanha J, Heath VJ, et al. Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation. Protein Eng 1991; 4: 773-83
27. Kuester K, Kovar A, Lupfert C, et al. Population pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer development. Br J Cancer 2008; 98: 900-6
28. Janmahasatian S, Duffull SB, Ash S, et al. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65
29. BrendelK,Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46: 221-34
30. Vanhoefer U, Tewes M, Rojo F, et al. Phase I study of the humanized anti-epidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 2004; 22: 175-84
31. DeSilva B, Smith W, Weiner R, et al. Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules. Pharm Res 2003; 20: 1885-900
32. Bonate PL. Pharmacokinetic-pharmacodynamic modeling and simulation. New York: Springer Science and Business Media, 2006
33. Bonate PL. The effect of collinearity on parameter estimates in nonlinear mixed effect models. Pharm Res 1999; 16: 709-17
34. Fliss G, Staab A, Tillmann C, et al. Population pharmacokinetic data analysis of cilobradine, an I(f) channel blocker. Pharm Res 2008; 25: 359-68
35. Yano Y, Beal SL, Sheiner LB. Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 2001; 28: 171-92
36. Michels GH. The use of collinearity diagnostics in PK model building [online]. Available from URL: http://www.ecpag.org/presentations/2006/0725/2- GregoryMichelsv4.pdf [Accessed 2008 Feb 27]
37. Belsley DA, Kuh E, Welsh RE. Regression diagnostics: identifying influential data and sources of collinearity. New York: John Wiley & Sons, Inc., 1980
38. Mager DE. Target-mediated drug disposition and dynamics. Biochem Pharmacol 2006; 72: 1-10
39. Hing JP, Piotrovsky V, Kimko H, et al. Pharmacokinetic simulation for switching from galantamine immediate-release to extended-release formulation. Curr Med Res Opin 2005; 21: 483-8
40. Aarons L, Karlsson MO, Mentre F, et al. Role of modelling and simulation in phase I drug development. Eur J Pharm Sci 2001; 13: 115-22
41. Rombout F, Aarons L, Karlsson M, et al. Modelling and simulation in the development and use of anti-cancer agents: an underused tool? J Pharmacokinet Pharmacodyn 2004; 31: 419-40
42. Bauer RJ, Guzy S, Ng C. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples. AAPS J 2007; 9: E60-83
43. Dingemanse J, Appel-Dingemanse S. Integrated pharmacokinetics and pharmacodynamics in drug development. Clin Pharmacokinet 2007; 46: 713-37
44. Gieschke R, Steimer JL. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development. Eur J Drug Metab Pharmacokinet 2000; 25: 49-58
45. Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165: 741-6
46. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001; 28: 43-7
47. Kloft C, Wallin J, Henningsson A, et al. Population pharmacokinetic- pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006; 12: 5481-90
48. Kloft C, Graefe EU, Tanswell P, et al. Population pharmacokinetics of sibrotuzumab, a novel therapeutic monoclonal antibody, in cancer patients. Invest New Drugs 2004; 22: 39-52